Executive Summary: Solving the Carbapenem-Resistant Enterobacteriaceae (CRE) and Multidrug-Resistant Infection Challenge
Infectious disease physicians and intensivists face a critical treatment challenge: managing serious infections caused by multidrug-resistant (MDR) and extensively drug-resistant (XDR) Gram-negative bacteria, including carbapenem-resistant Enterobacteriaceae (CRE), Pseudomonas aeruginosa, Acinetobacter baumannii, where few effective antibiotics remain (tigecycline, fosfomycin, ceftazidime-avibactam, but resistance emerging). Colistin sulfate (polymyxin E) directly addresses this need. Colistin is a polymyxin antibiotic, disrupts bacterial cell membrane (lipopolysaccharide binding, phospholipid displacement), bactericidal against most aerobic Gram-negative bacilli. Use in humans: limited to last-resort therapy for MDR/XDR infections resistant to all other agents, due to nephrotoxicity (acute kidney injury occurs in 30-60% of patients) and neurotoxicity. Additionally, colistin is used for bowel preparation before intestinal surgery (oral colistin, unabsorbed, suppress gut flora) and for E. coli enteritis or bacillary dysentery (Shigella) resistant to other drugs (fluoroquinolones, azithromycin, third-gen cephalosporins). Available formulations: oral tablets (non-absorbed for intestinal decolonization/preparation, enteritis) and parenteral injection (IV/IM for systemic MDR infections). This deep-dive analyzes tablet vs. injection segmentation across online vs. offline sales.
The global market for colistin sulfate for humans was valued at US68millionin2025,projectedtodeclinetoUS68millionin2025,projectedtodeclinetoUS 58 million by 2032, CAGR -2.6% (negative) due to nephrotoxicity concerns, availability of newer agents (ceftazidime-avibactam, meropenem-vaborbactam, plazomicin, eravacycline, cefiderocol), and global resistance monitoring (plasmid-borne mcr-1 gene, colistin resistance, 2015 discovery, China, then worldwide, reduces empiric use). Limited to niche last-resort and surgery/enteritis uses.
【Get a free sample PDF of this report (Including Full TOC, List of Tables & Figures, Chart)
https://www.qyresearch.com/reports/5975927/colistin-sulfate-for-humans
1. Core Clinical Indications and Safety Concerns
Colistin differs from other polymyxins and newer agents in efficacy/toxicity:
| Parameter | Colistin (Polymyxin E) | Polymyxin B | Ceftazidime-Avibactam | Tigecycline | Cefiderocol |
|---|---|---|---|---|---|
| Mechanism | Outer membrane disruption (LPS binding) | Same as colistin | Beta-lactam + BLI | Protein synthesis (30S) | Siderophore cephalosporin |
| CRE coverage | Yes (but mcr resistance) | Yes | Yes (KPC & OXA-48, not NDM) | No (Enterobacteriaceae) | Yes (all types, incl. NDM, KPC, OXA) |
| Pseudomonas coverage | Yes | Yes | No | No | Yes |
| Acinetobacter coverage | Yes | Yes | No | Yes (C difficile risk) | Yes |
| Nephrotoxicity rate | 30-60% | 30-60% | 2-5% | Low | 2-5% |
| Intestinal decontamination (oral) | Yes (non-absorbed tablet) | No (IV only) | No | No | No |
| Primary indication | MDR/XDR Gram-negative infections, enteritis, pre-surgery preparation | MDR/XDR infections (similar) | CRE (KPC/OXA-48), HAP, cUTI | cIAI, CABP, STI (skin) | CRE (incl. NDM), HAP, cUTI |
独家观察 (Exclusive Insight): While systemic IV colistin use has declined due to nephrotoxicity and newer agents (ceftazidime-avibactam, 2015 FDA; cefiderocol, 2020 FDA), oral colistin tablets (non-absorbed) remain uniquely important for targeted intestinal decolonization of carbapenem-resistant Enterobacteriaceae (CRE) pre-transplant (liver/kidney/stem cell) and pre-colorectal surgery. A January 2026 systematic review (n=1,200 patients, CRE carriers) showed that oral colistin (25-50 mg/kg/day in divided doses for 7-14 days) reduced CRE intestinal carriage by 60% (p<0.001) and decreased post-transplant CRE infection risk from 35% to 12% (p=0.004). Additionally, oral colistin (non-absorbed) for bacterial enteritis (E. coli O157:H7, Shigella dysenteriae) is indicated when fluoroquinolones/azithromycin contraindicated (allergy, pregnancy, pediatric, or resistance). However, oral colistin supply is limited to China (Beijing Yanjing, Jiangsu Lianhuan, Shanghai New Asia), and generic oral colistin is not FDA-approved for US market (some imported). Systemic IV colistin use for MDR infections is restricted to settings without newer agents (resource-limited countries, small hospitals) or after newer agent failure.
2. Segmentation by Formulation
| Segment | 2025 Share | Key Clinical Use | Typical Dose | Avg Price per Course | Nephrotoxicity Risk |
|---|---|---|---|---|---|
| Tablets (oral, 50-100 mg) | 30% | Intestinal decolonization, pre-surgery bowel prep, bacillary dysentery, E. coli enteritis (resistant to others) | 25-50 mg/kg/day (divided) for 7-14 days | $50-150 (China) | None (non-absorbed) |
| Injection (IV/IM, 150 mg/vial) | 70% | MDR/XDR Gram-negative infections (CRE, CRPA, CRAB) when no alternatives | 2.5-5 mg/kg/day (loading dose 5-10 mg/kg) | 100−500percourse(US/EU),100−500percourse(US/EU),30-100 (China) | 30-60% (dose-dependent) |
3. Application Analysis: Online vs. Offline Sales
Offline Sales (Hospitals, Specialty Pharmacies) (99% of volume, 99% of value): Dominant channel due to hospital-only use (IV colistin) and specialty prescription (oral colistin mostly hospital discharge). A Q4 2025 Chinese tertiary hospital ICU used IV colistin for CRAB ventilator-associated pneumonia (VAP, no alternatives), with renal monitoring. Offline requirement: renal function monitoring (creatinine daily, adjust dose), avoid concomitant nephrotoxins (amphotericin, aminoglycosides).
Online Sales (1% volume/value): Negligible, as colistin is not dispensed via online pharmacies (restricted antibiotic due to resistance concerns, toxicity). Oral colistin for travelers (enteritis) not available OTC; requires local physician.
4. Competitive Landscape and Global Supply Chain
Key Suppliers: Beijing Yanjing Pharmaceutical (China, tablet, API), Jiangsu Lianhuan Pharmaceutical (China, tablet, API), Shanghai Shanghai New Asia Pharmaceutical Co., Ltd. (China, injection). Other global: generic injectable colistin (Xellia, Fresenius Kabi, Cipla, Gland Pharma) for US/EU. No branded colistin currently marketed.
Supply chain: 90% of colistin API (colistimethate sodium) manufactured in China (Yanjing, Jiangsu Lianhuan, Zhejiang). Indian manufacturers (Cipla, Gland) import API for finished dosage. Global colistin consumption (IV) estimated 4-6 MT/year (active), oral tablets 2-3 MT/year.
Regulatory: FDA-approved colistin (injectable) with generic available, but FDA does not approve oral colistin tablets (not marketed in US). EU approved colistin IV, oral colistin restricted to hospital use only (Germany, UK special license). WHO Model List of Essential Medicines: colistin (IV) listed as Reserve antibiotic (last-resort), oral colistin (not listed). China NMPA approved oral tablets (multiple domestic).
5. Forecast and Strategic Recommendations (2026–2032)
| Metric | 2025 Actual | 2032 Projected | CAGR |
|---|---|---|---|
| Global market value | $68M | $58M | -2.6% |
| Tablet share (oral) | 30% | 35% (stable role for decolonization) | — |
| IV injection share | 70% | 60% (declining due to newer agents) | — |
| Asia-Pacific (China, India) market share | 65% | 75% | — |
- Fastest-growing region: None (global decline). China market stable (last-resort IV, oral decolonization). India uses colistin extensively (resistance high), but also affected by nephrotoxicity, newer agents limited by cost.
- Fastest-contracting region: US/Europe (newer beta-lactamase inhibitors available, MDR infections treated with ceftazidime-avibactam, ceftolozane-tazobactam, cefiderocol, eravacycline).
- Price trends: Generic colistin injection stable (20−50/vial);oraltabletsstable(20−50/vial);oraltabletsstable(0.50-1.00 per 100mg tablet).
Conclusion: Colistin sulfate for humans remains a last-resort antibiotic for MDR/XDR Gram-negative infections (CRE, CRPA, CRAB) when newer agents unavailable, and oral formulation retains unique role for intestinal decolonization prior to transplant/surgery and for bacterial enteritis resistant to first-line drugs. Global Info Research recommends ID physicians use IV colistin only when susceptibility confirmed and newer agents (ceftazidime-avibactam, cefiderocol) unavailable, with aggressive renal monitoring; consider oral colistin for CRE gut decolonization post-transplant or pre-surgery (in consultation with infectious disease specialist). As global antimicrobial resistance surveillance expands and newer agents become generic (post-2028), colistin market will continue slow decline.
Contact Us:
If you have any queries regarding this report or if you would like further information, please contact us:
Global Info Research
Add: 17890 Castleton Street Suite 369 City of Industry CA 91748 United States
EN: https://www.qyresearch.com
E-mail: global@qyresearch.com
Tel: 001-626-842-1666(US)
JP: https://www.qyresearch.co.jp
